EI

259.5

-1.48%↓

SAN

84.4

-1.16%↓

MRK1

108.7

+0.83%↑

SHL.DE

47.28

0%↓

ARGX

603.4

+0.2%↑

EI

259.5

-1.48%↓

SAN

84.4

-1.16%↓

MRK1

108.7

+0.83%↑

SHL.DE

47.28

0%↓

ARGX

603.4

+0.2%↑

EI

259.5

-1.48%↓

SAN

84.4

-1.16%↓

MRK1

108.7

+0.83%↑

SHL.DE

47.28

0%↓

ARGX

603.4

+0.2%↑

EI

259.5

-1.48%↓

SAN

84.4

-1.16%↓

MRK1

108.7

+0.83%↑

SHL.DE

47.28

0%↓

ARGX

603.4

+0.2%↑

EI

259.5

-1.48%↓

SAN

84.4

-1.16%↓

MRK1

108.7

+0.83%↑

SHL.DE

47.28

0%↓

ARGX

603.4

+0.2%↑

Search

Laboratorios Farmaceuticos Rovi SA

Closed

SectorHealthcare

58.1 -0.34

Overview

Share price change

24h

Current

Min

57.75

Max

58.6

Key metrics

By Trading Economics

Income

3.9M

27M

Sales

4.8M

160M

P/E

Sector Avg

22.51

35.724

EPS

0.423

Dividend yield

1.62

Profit margin

16.767

Employees

2,188

EBITDA

4.2M

35M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+38.56% upside

Dividends

By Dow Jones

Next Earnings

6 lis 2025

Market Stats

By TradingEconomics

Market Cap

161M

3B

Previous open

58.44

Previous close

58.1

News Sentiment

By Acuity

7%

93%

5 / 372 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

29 sie 2025, 18:43 UTC

Major Market Movers

Privia Health Shares Advance on Outlook Bump From Medicare Savings

29 sie 2025, 15:07 UTC

Acquisitions, Mergers, Takeovers

Strathcona Resources to Increase Minority Stake in MEG Energy, Vote Against Cenovus Buyout Plan

29 sie 2025, 20:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Auto & Transport Roundup: Market Talk

29 sie 2025, 20:24 UTC

Earnings

Earnings Season Highlights on Tariffs, Consumer Spending, and More -- Barrons.com

29 sie 2025, 20:17 UTC

Earnings

These Stocks Moved the Most Today: Alibaba, Marvell, Affirm, Nvidia, Dell, Autodesk, Ambarella, IREN, and More -- Barrons.com

29 sie 2025, 19:18 UTC

Market Talk

Oil Futures End Week With Modest Gains -- Market Talk

29 sie 2025, 18:59 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

29 sie 2025, 18:36 UTC

Earnings

These Were the Best & Worst S&P 500 Stocks in August -- Barrons.com

29 sie 2025, 18:26 UTC

Earnings

What the Stock Market Learned About Earnings and Consumers This Summer -- Barrons.com

29 sie 2025, 17:48 UTC

Market Talk

U.S. Oil Rig Count Increases By 1 to 412 -- Market Talk

29 sie 2025, 17:10 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Regulator Firing Clears Path for Union Pacific-Norfolk Southern Deal -- Market Talk

29 sie 2025, 16:57 UTC

Earnings

These Stocks Are Moving the Most Today: Alibaba, Marvell, Affirm, Nvidia, Dell, Autodesk, Ambarella, IREN, and More -- Barrons.com

29 sie 2025, 16:30 UTC

Acquisitions, Mergers, Takeovers

Celsius Stock Is Spiking After PepsiCo Increases Stake -- Barrons.com

29 sie 2025, 16:28 UTC

Acquisitions, Mergers, Takeovers

BBVA: Adjustment Intended to Maintain Equivalent Economic Terms of Offer Following Dividend Payments by Sabadell

29 sie 2025, 16:27 UTC

Acquisitions, Mergers, Takeovers

BBVA: Adjustment Outlined in Announcement on May 9, 2024

29 sie 2025, 16:26 UTC

Acquisitions, Mergers, Takeovers

BBVA Now Offering 1 Newly Issued Ordinary BBVA Share and EUR0.70 in Cash for Every 5.5483 Ordinary Shares of Sabadell

29 sie 2025, 16:25 UTC

Acquisitions, Mergers, Takeovers

BBVA: Adjustment Factors in Interim Dividend Paid by Sabadell to Its Shareholders

29 sie 2025, 16:24 UTC

Acquisitions, Mergers, Takeovers

BBVA Adjusts Offer for Banco de Sabadell

29 sie 2025, 16:23 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Strathcona's Power Play in MEG Energy Jeopardizes Cenovus Deal -- Market Talk

29 sie 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

29 sie 2025, 16:06 UTC

Market Talk

Gold Futures Gain as U.S. Inflation Data Boost Rate Cut Hopes -- Market Talk

29 sie 2025, 15:12 UTC

Market Talk
Earnings

Best Buy Surprise Comp Growth Potentially Driven by Switch 2 -- Market Talk

29 sie 2025, 15:09 UTC

Earnings

Small-Cap Stocks Are Rallying Again. This Time It's Real. -- Barrons.com

29 sie 2025, 15:01 UTC

Market Talk

Canadian Economy Expected to Slow But Grow in 2H -- Market Talk

29 sie 2025, 14:49 UTC

Earnings

These Stocks Are Moving the Most Today: Marvell, Dell, Nvidia, Alibaba, Affirm, Autodesk, Ambarella, IREN, and More -- Barrons.com

29 sie 2025, 14:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

29 sie 2025, 14:49 UTC

Market Talk

Canada May Avoid Contraction in 3Q, But Is Expected to Struggle -- Market Talk

29 sie 2025, 14:48 UTC

Earnings

Marvell Stock Tumbles. Why the AI Chip Player Keeps Disappointing the Market. -- Barrons.com

29 sie 2025, 14:43 UTC

Market Talk

Rise in Canadian Household Spending May Not Worry Central Bank -- Market Talk

29 sie 2025, 14:38 UTC

Market Talk

With Canada's Economy Soft, Central Bank Easing Looks Likely -- Market Talk

Peer Comparison

Price change

Laboratorios Farmaceuticos Rovi SA Forecast

Price Target

By TipRanks

38.56% upside

12 Months Forecast

Average 80.85 EUR  38.56%

High 90 EUR

Low 71.7 EUR

Based on 2 Wall Street analysts offering 12 month price targets forLaboratorios Farmaceuticos Rovi SA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

2

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

51.1 / N/ASupport & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

5 / 372 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.